The Patent Finder

Pitney Pharmaceuticals Pty Limited

8 patents currently held · Updated Nov 17, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Mar 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 21, 2026
    The maintenance fee for Anticancer agent comprising aminoacetonitrile compound as active ingredient (US 10,292,960) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
  • 1 fee due Feb 27, 2027
    The maintenance fee for Anti-cancer agent comprising aminoacetonitrile compound as active ingredient (US 10,391,076) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 1 fee due Oct 12, 2027
    The maintenance fee for Kinase inhibitors for the treatment of cancer (US 9,308,193) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

PatentTitleStatus Expires Confidence
US 9,308,193Kinase inhibitors for the treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,790,176Compounds for the treatment of mTOR pathway related diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,053,422Compounds for the treatment of mTOR pathway related diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,907,778Anticancer agent comprising aminoacetonitrile compound as active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,292,960Anticancer agent comprising aminoacetonitrile compound as active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,833,431Pharmaceutical combinations for the treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,391,076Anti-cancer agent comprising aminoacetonitrile compound as active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,213,957Use of Aminoacetonitrile Compounds for the Treatment of Infection and Disease
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 1 patent in force now held by others · 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited